

CLAIMS

WHAT IS CLAIMED IS:

1. A method of treating restless legs syndrome in a patient, comprising administering to said patient in need of treatment a therapeutically effective amount of bupropion or pharmaceutically acceptable salts thereof.
2. The method according to claims 1, wherein bupropion is administered by intravenously, transdermally, or orally.
- 10 3. The method according to claims 1, wherein bupropion is administered in the form of tablet, cachet, capsule, troche, dispersion, suspensions, or solutions.
4. The method according to claim 1 wherein bupropion is administered orally.
- 15 5. The method according to claim 1 wherein the amount administered is from about 10 mg to about 750 mg.
6. The method according to claim 5 wherein the amount administered is from about 50 mg to about 600 mg.
- 20 7. The method according to claim 6 wherein the amount administered is from about 60 mg to about 450 mg.
8. The method according to claim 1 wherein bupropion is administered as the hydrochloride salt.
- 25 9. The method according to claim 1 wherein bupropion is administered in a sustained or controlled release formulation.
- 30 10. The method according to claim 1 wherein the pharmaceutically acceptable salt of bupropion is (\pm)-bupropion hydrochloride.

11. The method according to claim 1 wherein the pharmaceutically acceptable salt of bupropion is (\pm)-bupropion maleate.

5 12. The method according to claim 1 wherein the bupropion is (-)-bupropion or pharmacologically acceptable salts thereof.

10 13. The method according to claim 12 wherein the amount of (-)-bupropion or a pharmaceutically acceptable salt thereof is greater than approximately 90% by weight of the total amount of bupropion.

14. The method according to claim 12 wherein the amount of (-)-bupropion or a pharmaceutically acceptable salt thereof, substantially free of its (+)-stereoisomer, is administered together with a pharmaceutically acceptable carrier.

15 15. The method according to claim 12 wherein (-)-bupropion is administered as the hydrochloride salt.

16. The method of claim 1 wherein (-)-bupropion is administered in a sustained or controlled release formulation.

20 17. Use of bupropion or pharmacologically acceptable salts thereof for the preparation of a medicament useful for treating restless legs syndrome in a patient.

18. The use of claim 17, wherein the compound is (\pm)-bupropion hydrochloride.

25 19. The use of claim 17, wherein the compound is (\pm)-bupropion maleate.

20. The use of claim 17, wherein the compound is (-)-bupropion or pharmacologically acceptable salts thereof.